In a previous experiment (Lader and Wing, 1964) , the palmar skin resistance was recorded in 20 patients with anxiety states and 20 normal controls. After a rest period, 20 identical auditory stimuli were applied automatically at intervals varying from 45 to 80 seconds to form a standard habituation procedure.
Three aspects of the skin resistance were studied. First, the background level, which is a measure of normal continuing sweat-gland activity, was analysed as its reciprocal, skin conductance. It was found that as the experiment proceeded the level of skin conductance tended to fall in the normal group, i.e., activity dropped, whereas it tended to rise in the group of patients. Secondly, the responses to the auditory stimuli were quantified and it was found that these responses (psychogalvanic reflexes) tended to diminish with repetition of the stimuli, i.e.. they habituated. It was found that the normal group had large early responses which rapidly habituated whereas the patients had smaller early responses which persisted in size with little evidence of habituation. Thirdly, spontaneous skin conductance fluctuations were more frequent in the patients than in the normal group throughout the whole experiment.
These findings supported Malmo's theory (1957 Malmo's theory ( , 1959 that patients with anxiety states are chronically 'over-aroused'. However, we have elaborated the 'over-arousal' theory in that defective habituation was regarded as an important cause of the excess activity in the central nervous system. Thus, in the population at large, the rate of habituation is regarded as a property of the central nervous system which is distributed on a continuum and any individual's locus on that continuum is mainly genetically determined. In normal people, stressful situations cause a rise in the level of activity in the central nervous system which quickly falls again. In some individuals with defective habituation, stressful situations cause a rise in this activity which is greatly prolonged. This theory would predict that treatment of patients with anxiety states with sedative drugs would tend to return the physiological patterns in the direction of normal. It would also predict that such treatment would cause improvement in some, at least, of the clinical symptoms in parallel with the physiological changes.
Hamilton (1959) discussed the rating of clinical progress in anxious patients. He pointed out that change in the content of such patients' symptoms is rare, but the intensity with which they are experienced may be altered by treatment. He therefore recommended scales designed to rate the severity of symptoms for use in clinical trials. Raymond, Lucas, Beesley, O'Connell, and Roberts (1957) compared the effects of five drugs on anxious patients using a simple five-point scale to record overall improvement or deterioration. Amylobarbitone sodium 100 mg. t.d.s. was the only drug that was significantly better than the placebo. These workers did not examine individual symptoms. However, Hargreaves, Hamilton, and Roberts (1958) and Hamilton (1958) , using benactyzine to treat patients with anxiety states, found that some symptoms improved on the drug while others did not. This suggests that the use of one overall rating of change may not be precise enough for the evaluation of drug effects.
The most widely used sedatives in the treatment of anxiety states are the barbiturates and the most usual barbiturate is amylobarbitone sodium. The purpose of the experiments to be described was to ascertain the effects of a week's treatment with amylobarbitone sodium compared with a placebo on the physiological measures and clinical symptoms of patients with anxiety states. The experiment was also in the nature of an assessment of the sensitivity of the measures to barbiturate. It was hoped that the physiological and clinical measures would prove sufficiently sensitive to enable formal comparative bioassays of sedatives to be attempted in later experiments. Physiological recordings were made after a week's treatment with barbiturate and, again, after a second week's treatment with placebo. In addition, clinical changes were assessed by means of rating scales based on each patient's own symptoms.
PHYSIOLOGICAL MEASUREMENTS
The same 20 patients with anxiety states studied in the experiments reported previously (Lader and Wing, 1964) were used again, and the diagnostic criteria applied are set out in full in that report. Of the 10 males, eight patients had 'free-floating' anxiety, one had anxiety together with some symptoms of mild depression, and one had 'situational' anxiety, i.e., anxiety confined to certain specific situations. Seven of the 10 female patients suffered from 'free-floating' anxiety, one had mild depressive features in addition to anxiety, and two had 'situational' anxiety states. (Lader, 1964 DAILY RATING OF SYMPTOMS The method used was a modification of scales described by Rosner, Levine, Hess, and Kaye (1955) and Black (1959) . One of the forms used is shown in Figure 1 .
At the first interview, the symptoms of the patient described in his own words were entered in the spaces on the left hand side of the form: for example, 'thumping of the heart', 'a feeling of anxiety which never goes away', 'afraid to go on the underground', 'tiredness and loss of interest'.
When the list was completed, the patient was asked to make a mark on the horizontal lines (all 10 cm. in length) to show how severe each of his symptoms had been for the few days before the beginning of the experiment during which no drug had been given. The WEEKLY RATING OF SYMPTOMS At the end of each week, after completion of the physiological tests, the patients were asked if there had been any change in their symptoms. A nine-point scale was used to rate each symptom with 0 as no change, -4 as much worse, and +4 as much better. For both weeks, the comparison was made between the present state and the state before the trial started. Patients were not asked to compare the second week with the first. SIDE EFFECTS Each patient was asked for details of side effects when the weekly rating was completed.
EXPERIMENTAL CONDITIONS AND PROCEDURE
The patients sat in a comfortable armchair in a soundprotected room, the temperature of which was controlled ABSENT MODERATE VERY SEVERS at 22-240C. The recording equipment was in an adjacent room from which the patients could be observed through a one-way screen. The patients were aware that they were under observation throughout the experiment. Each patient reported to the laboratory at the end of ABSENT MODERATE VERY SEVERE each week's treatment bringing with him the completed forms for that week. He was brought into the experimental room and the electrodes were affixed. During this time the patient was rated for overt anxiety. The patient was told that the procedure would be the same as that of the pre-drug test: a rest period followed by a series of sounds ABSENT MODERATE VERY SEVERE to which he was to make no active response.
The room lights were dimmed, the patient was left alone and recording started. After 11 minutes, 20 auditory stimuli were applied and recording terminated one minute after the last stimulus. The electrodes were then removed ABSENT MODERATE VERY SEVERE and the patient was questioned regarding the effects of the previous week's treatment on his symptoms.
ANALYSIS OF SKIN RESISTANCE RECORDINGS
SKIN CONDUCTANCE LEVELS The skin resistance level ABSENT MODERATE VERY SEVERE was read at one-minute intervals before the stimuli started, just before each of the 20 stimuli and once at the end of the experiment. For reasons outlined elsewhere (Lader, 1964) , the resistance values (in kilohms) were converted to log conductance values (in log micromhos). The criterion used was a log conductance change of 0 003 log es mhos and the technique for applying such a criterion to a resistance trace has been explained previously (Lader, 1964) .
The 32 counts were added into eight groups of four, three during the rest period and five during the stimuli.
ANALYSIS OF RATING SCALES
DAILY RATINGS For each symptom, the distance from the left hand end of the line to the mark made by the patient was measured to the nearest centimetre.
Since each patient provided his own description of his symptoms, direct comparisons could not be made from the raw data. However, it was found that all the symptoms could be grouped into four categories. 1 Physical symptoms, i.e., autonomic or muscular, such as palpitations or shakiness; 2 general anxiety (usually expressed as a 'feeling of fear'; 3 situational anxiety, e.g., dislike of travelling on public transport because of exacerbation of symptoms; 4 depressive symptoms. These were believed by the patients to be a consequence of their anxiety, and except in two cases, were given little prominence in the description of symptoms.
The distribution of the daily ratings was examined. It was found that, for each patient, ratings of symptoms classified under the same heading were sufficiently close to allow the scores to be combined. The mean was calculated to the nearest centimetre. If a symptom category was not represented a score of 0 was given.
A mean daily score for each symptom category was calculated from the ratings made on the last three days of each week. This was to allow for build-up of drug effects and for any possible carry over from the previous week which might have affected the first few days. The mean scores for each symptom category were subtracted from the baseline scores obtained at first interview, and this value was used in the final statistical analysis.
WEEKLY RATING Scores were given on the nine-point scale as described previously and symptoms were combined into categories as above. The mean was taken to the nearest whole number. These scores were obtained as comparisons with the baseline, so no further correction was needed. STATISTICAL 
ANALYSIS
The distributions of the data obtained from the physiological measures and from the clinical rating scales were sufficiently close to normality to allow parametric statistics to be used. A split-plot type of analysis of variance was used (Cochran and Cox, 1957) . Both the drug effects and occasion effects were tested against the within-patient residual error variance. As none of the occasion effects was significant, only drug effects will be presented. Fig. 2 Psycho-galvanic reflexes (sweat-gland responses) Previous work had shown that habituation of the psycho-galvanic reflexes tended to follow an exponential course (Lader, 1964) . Therefore, the mean psycho-galvanic reflexes (ordinate Y) were plotted against the logarithm of the stimulus number (abscissa X) as shown in Figure 4 . The first responses are distinct and they were analysed separately. The mean responses to stimuli nos. 2 to 20 inclusive are rather scattered but they lie around straight lines for both drug and placebo. The regression lines of mean responses on log stimulus numbers were calculated in the usual way (Snedecor, 1956) (Snedecor, 1956) . Two scores termed 'habituation scores' (H scores) were obtained for each patient, one for the placebo habituation sequence and one for the barbiturate. The H score, then, is the slope of habituation corrected for the Y intercept.
RESULTS PHYSIOLOGICAL MEASUREMENTS In
The statistical results are given in Table I . There is no significant difference between the treatments for either the size of the first responses or the a values. The rate of habituation (b value) is significantly increased by the barbiturate as compared with placebo (P<0 05). The corrected rates of habituation, the H scores, are greater for the drug than the placebo at a slightly higher level of significance (P<0.02).
The H scores did not yield a high discrimination between the treatments. Of the 20 patients, in 15 <0-02 the rate of habituation was more rapid for the barbiturate than for the placebo; in five the placebo rate was the more rapid.
Habituators and non-habituators When the regression slopes (b values) were being calculated, the statistical significance of each regression slope could be tested (Snedecor, 1956) . If There is a significant difference between the two treatments at the start of the experiment but this significance is lost in the remainder of the rest period (see Table II ). The significance is regained at the next point (time 14) and it persists throughout the rest of the experiment. The numbers of fluctuations at times 26 and 30 were added together to give a variable which will subsequently be referred to as 'fluctuations at end of experiment'. An F ratio of 12-27 (1,16 d.f.; P<001) was obtained for this variable. For 18 out of the 20 patients, the number of fluctuations at end of experiment were lower with the amylobarbitone sodium than with placebo. In only two was the number lower with placebo.
Discriminant-function analysis and overt anxiety ratings Three variables appeared to be fairly sensitive to drug effects. They were total conductance change, H score, and fluctuations at end of experiment. These variables were also those which had discriminated best between the patients with anxiety states and the normal subjects in the previous predrug experiment (Lader and Wing, 1964) . In that experiment the three variables had been combined in such a way as to yield the maximum discrimination between the groups using the statistical technique known as discriminant-function analysis (Fisher, 1954) . The equation which was derived was:
Discriminant-function score (pre-drug) = -0-074 (total conductance change) + 0-485 (H score) + 0-001278 (fluctuations at end)
The higher the D score, the greater was the composite physiological activity. In the present experiment, the data for each patient were inserted into the above equation. Thus, two scores were obtained for each patient, one for the placebo occasion (D placebo) and one for the amylobarbitone sodium occasion (D amylobarb.). Also, a D score had been obtained before the treatment started (D pre-drug) (Lader and Wing, 1964 Siegel, 1956) .
The rank correlation coefficient between the overt anxiety ratings on the placebo occasion and the D placebo scores was +0X28 (not significant). The rank correlation between the amylobarbitone sodium anxiety ratings and the D amylobarbitone scores was +0-60 (P<0 002). The correlation between the changes in overt anxiety ratings and the D change scores was +0-42 (P = 0-05). It may be concluded that the overt anxiety ratings on the barbiturate occasion but not on the placebo occasion are related to the equivalent measure of composite physiological activity; furthermore, there is a just significant relationship between improvement in overt anxiety with treatment and change in composite physiological activity. Table  III . The highest correlation was between the two ratings of physical symptoms and this was the only one to reach an acceptable level of significance.
COMPARISON BETWEEN EFFECT OF DRUG AND OF
PLACEBO Physical symptoms were rated as less severe during treatment with the drug than with the placebo. This was significant for both the daily and the weekly scores (see Table IV ). General symptoms of anxiety showed virtually no difference on the daily scores, and a slight advantage for the drug on the weekly score which was not significant.
Situational anxiety symptoms were also only slightly affected by the drug. For depressive symptoms, a slight insignificant advantage for the drug, as compared with the placebo, was found on the mean daily score; on the weekly rating the drug superiority was significant.
The scores for different symptoms cannot be compared. This is because all patients had physical symptoms, but did not necessarily have each of the other three possible symptom categories. The number of spontaneous fluctuations was ignificantly different from lessened by the barbiturate, i.e., the change was in anxifiyaand depression the direction of those levels obtaining in normal anxiety erioration son control subjects (Lader and Wing, 1964) . A similar ant deterioration on the 'normalizing' effect of amylobarbitone sodium on respiratory patterns was described by Coppen and reported side effects while Mezey (1960). They found that anxious patients have ir complained of daytime inefficient respiration as compared with normals and :-headed' feeling, and one that the respiratory inefficiency tends to be miniirring soon after taking mized by the administration of one dose of 200 mg. Ifthe six patients had the of amylobarbitone sodium. placebo (drowsiness and Reactivity, as assessed by the size of the first psyively). One other patient chogalvanic reflex and the a value, was not affected k-headed' on the placebo by the barbiturate. Habituation was accelerated sig--re of little consequence nificantly but the mean effect was small. This inroman who was extremely crease in the rate of habituation is to be expected from the results obtained in normal subjects (Lader, SSION 1964) . In these experiments, it was found that cyclobarbitone accelerated habituation and the used was the balanced acceleration bore a rectilinear relationship to the dose each patient receives both of drug. hat is, he acts as his own Of the variables, the habituation score was the oly used in the evaluation least consistently affected by the drug, five out of 20 ents. The alternative, that patients habituating more rapidly with the placebo. ients each given one drug, It might be argued that this inconsistency was due to as it is necessary to match the complex mathematical derivation of the variable s as possible. Lewis (1958) obscuring the drug effect. However, in the previous ic groups for this purpose experiment (Lader and Wing, 1964) , the H score ce they should be at least discriminated best between anxious patients and of sex, age, intelligence, normal subjects. It Significant 'non-specific' improvements produced by the placebo were seen in the daily but not the weekly ratings. The baseline for the former was assessed at the first interview following the unfamiliar physiological tests, so the symptoms may on that occasion have been rated as more severe than usual. Weekly ratings were made on the second and third visits when the patients were accustomed to the routine, and knew that nothing unpleasant would occur. The tablets were given without any promises of positive effects and this may have reduced the tendency to report non-specific improvement.
Contrary to the findings of Black (1959) changes with the placebo were not related to the order in which the tablets were given.
In summary, amylobarbitone sodium alters several physiological variables and lessens the severity of one type of symptom group as compared with placebo. The change in the physiological variables is in the direction of those mean values occurring in normal control subjects (Lader and Wing, 1964) . The results may be interpreted as meaning that the levels of some aspects of activity of the central nervous system are diminished by barbiturate therapy. The D score equation, originally obtained to discriminate between anxious patients and normal patients, was also successful at discriminating between the patients when they were on amylobarbitone sodium therapy and placebo therapy. As far as the physiological variables measured in the present experiments are concerned, it appears that the patients with anxiety states are quantitatively different from normals and that that difference can be lessened by sedatives. The 'normalizing' effect was not great which is in accord with the small though significant clinical changes.
In the previous paper it was postulated that the rate of habituation was of importance in the pathogenesis of anxiety states. Those people who habituated slowly were more prone to develop persisting overactivity of the central nervous system perceived in 'consciousness' as the emotion of anxiety. This activity could be damped down by general central nervous system depressant drugs such as barbiturates with amelioration of perceived anxiety. Lowering of skin conductance fluctuation level by a sedative was found in the present experiment. The rate of habituation was relatively less affected by the barbiturate, and this, considered in conjunction with the fact tha' the clinical changes were limited, is consistent with the hypothesis. A corollary of the hypothesis is that a drug which has a specific anti-anxiety effect, that is, one which produces marked clinical changes in all the symptom groups, should markedly accelerate the rate of habituation of patients. So The background skin conductance level tended to rise throughout the recording session on the placebo occasion whereas it dropped on the amylobarbitone sodium occasion. Habituation of the psychogalvanic reflexes to the stimuli was more rapid with the barbiturate and the number of spontaneous skin conductance fluctuations was lowered by the barbiturate.
The patients made daily ratings of the severity of their symptoms and weekly ratings of changes in the same symptoms were made at interview after the physiological tests. The symptoms were classified into four categories: physical (i.e., autonomic or muscular), general feelings of anxiety, situational anxiety, and depressive symptoms. Only the physical symptoms showed significant improvement on the drug as compared with the placebo.
The results were consistent with a theory of the mechanism of anxiety based on the relationship between the rate of habituation and the level of activity of the central nervous system which had been outlined previously. 
